Liquid biopsy research advancements

Liquid biopsies offer a non-invasive method to detect and monitor tumors. Efforts are underway to develop liquid biopsy assays for early cancer detection, minimal residual disease testing (MRD), tumor profiling, and more. Despite significant promise, challenges persist in effectively identifying circulating tumor-derived DNA fragments (ctDNA) in the complex landscape of cell-free DNA (cfDNA) that pervades liquid biopsy samples. Twist Bioscience offers a suite of cutting-edge research solutions, each designed to help researchers improve ctDNA detection and the research of clinically relevant variants for developing NGS-based assays.